Drug Trial Radar · NCT07219212
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Jan 26, 2026
Primary completion
Jul 14, 2028
Study completion Jul 14, 2028
Sponsor
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).
Conditions
- Squamous Cell Carcinoma of Head and Neck
Interventions
JNJ-90301900Drug
JNJ-90301900 will administered via intratumoral and/or intranodal injection.
CisplatinDrug
Cisplatin will be administered intravenously.
Intensity Modulated Radiation Therapy (IMRT)Radiation
IMRT radiation therapy will be administered.
CarboplatinDrug
Carboplatin will be administered intravenously.
PaclitaxelDrug
Paclitaxel will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to approximately 2 years 14 weeks
Locations
25 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
City of Hope
Duarte, California · Recruiting
University of California at San Diego Moores Cancer Center
La Jolla, California · Suspended
Mayo Clinic
Jacksonville, Florida · Recruiting
Moffit Cancer center
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Hopital De La Cavale Blanche
Brest, France · Recruiting
CHU de Grenoble
La Tronche, France · Recruiting
Centre Oscar Lambret
Lille, France · Recruiting
Hopital La Timone
Marseille, France · Recruiting
Centre Henri Becquerel
Rouen, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Hiroshima University Hospital
Hiroshima, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Japan · Recruiting
Aichi Cancer Center
Nagoya, Japan · Recruiting
Shizuoka Cancer Center
Shizuoka, Japan · Recruiting
Tokyo Medical University Hospital
Tokyo, Japan · Recruiting
ICO L'Hospitalet - Hospital Duran i Reynals
Barcelona, Spain · Recruiting
Hosp. Gral. Univ. Gregorio Maranon
Madrid, Spain · Recruiting
Hosp Univ Fund Jimenez Diaz
Madrid, Spain · Recruiting
Hosp. Univ. I Politecni La Fe
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.